Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06501573
PHASE1

A Study of SGB-9768 in Adult Healthy Volunteers

Sponsor: Suzhou Sanegene Bio Inc.

View on ClinicalTrials.gov

Summary

This study is a randomized, double-blind, placebo-controlled single ascending dose study of SGB-9768 in healthy volunteers. The purpose is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SGB-9768.

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-9768 in Healthy Volunteers

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

37

Start Date

2024-08-06

Completion Date

2025-10-17

Last Updated

2025-01-22

Healthy Volunteers

Yes

Interventions

DRUG

SGB-9768

SGB-9768 for sc injection

OTHER

Placebo

sterile normal saline (0.9% NaCl) for sc injection

Locations (1)

Huashan hospital

Shanghai, China